<SEC-DOCUMENT>0001213900-17-010871.txt : 20171024
<SEC-HEADER>0001213900-17-010871.hdr.sgml : 20171024
<ACCEPTANCE-DATETIME>20171024163118
ACCESSION NUMBER:		0001213900-17-010871
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20171024
DATE AS OF CHANGE:		20171024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-216748
		FILM NUMBER:		171151239

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>f424b31017atm_actinium.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>under the
Securities Act of 1933</B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>in connection with</B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Registration Statement No. 333-216748</B></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white; color: #DE1A1E"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 103px; width: 428px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$75,000,000</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with the terms of the
At Market Issuance Sales Agreement entered into with FBR Capital Markets &amp; Co., or FBR, dated March&nbsp;16, 2017, which we
refer to as the sales agreement, we may offer and sell shares of our common stock, par value $0.001 per share, having an aggregate
offering price of up to $75,000,000 from time to time through FBR, acting as agent.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Our common stock is presently traded on the
NYSE American under the symbol &ldquo;ATNM.&rdquo; On October 23, 2017, the last reported sale price of our common stock was $0.72
per share.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sales of our common stock, if any,
under this prospectus will be made by any method permitted that is deemed an &ldquo;at the market offering&rdquo; as defined in
Rule 415 under the Securities Act of 1933, as amended. FBR will act as our sales agent using commercially reasonable efforts consistent
with its normal trading and sales practices. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FBR will be entitled to compensation
at a commission rate of 3% of the gross sales price per share sold. In connection with the sale of the common stock on our behalf,
FBR may be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act of 1933, as amended, and the compensation
of FBR may be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution
to FBR with respect to certain liabilities, including liabilities under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Investing in our securities involves
a high degree of risk. These risks are discussed in this prospectus under &ldquo;Risk Factors&rdquo; beginning on page&nbsp;S-9
and in the documents incorporated by reference into this prospectus.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy
of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FBR</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is October
24, 2017</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="TableOfContents"></A>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top; width: 93%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 7%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-2</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">THE OFFERING</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">RISK FACTORS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-11</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-12</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">DILUTION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">DIVIDENDS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-19</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-20</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">EXPERTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-20</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-20</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-21</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus is part of a registration
statement on Form S-3 that we filed with the Securities and Exchange Commission using a &ldquo;shelf&rdquo; registration process.
This prospectus relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge
you to carefully read this prospectus, together with the information incorporated by reference as described under the heading &ldquo;Where
You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference.&rdquo; These documents contain
important information that you should consider when making your investment decision.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus describes the specific
terms of the common stock we are offering and also adds to and updates information contained in the documents incorporated by reference
into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand,
and the information contained in any document incorporated by reference in this prospectus, on the other hand, you should rely
on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document
having a later date&mdash;for example, a document incorporated by reference into this prospectus&mdash;the statement in the document
having the later date modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should only rely on the information
contained or incorporated by reference in this prospectus and any issuer free writing prospectus that we may authorize for use
in connection with this offering. No person has been authorized to give any information or make any representations in connection
with this offering other than those contained or incorporated by reference in this prospectus and any related issuer free writing
prospectus in connection with the offering described herein and therein, and, if given or made, such information or representations
must not be relied upon as having been authorized by us. Neither this prospectus nor any related issuer free writing prospectus
shall constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful
for such person to make such an offering or solicitation. This prospectus does not contain all of the information included in the
registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration
statement, including its exhibits.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should read the entire prospectus
and any related issuer free writing prospectus, as well as the documents incorporated by reference into this prospectus or any
related issuer free writing prospectus, before making an investment decision. Neither the delivery of this prospectus or any issuer
free writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated
by reference herein or in any issuer free writing prospectus is correct as of any date subsequent to the date hereof or of such
issuer free writing prospectus. You should assume that the information appearing in this prospectus or any document incorporated
by reference is accurate only as of the date of the applicable documents, regardless of the time of delivery of this prospectus
or any sale of securities. Our business, financial condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>This summary provides an overview
of selected information contained elsewhere or incorporated by reference in this prospectus and does not contain all of the information
you should consider before investing in our common stock. You should carefully read the prospectus, the information incorporated
by reference and the registration statement of which this prospectus is a part in their entirety before investing in our common
stock, including the information discussed under &ldquo;Risk Factors&rdquo; in this prospectus and the documents incorporated by
reference and our financial statements and notes thereto that are incorporated by reference in this prospectus. As used in this
prospectus, unless the context otherwise indicates, the terms &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us,&rdquo; or &ldquo;the
Company&rdquo; refer to Actinium Pharmaceuticals, Inc., a Delaware corporation, and its subsidiaries taken as a whole.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>The Company</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Business Overview</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company focused on developing and commercializing targeted therapies for safer myeloablation and conditioning of the bone marrow
prior to a bone marrow transplant (BMT) and for the targeting and killing of cancer cells. We are currently conducting clinical
trials for our three product candidates, Iomab-B, Actimab-A and Actimab-M, as well as performing research on other potential drug
candidates utilizing our proprietary alpha-particle technology platform. &nbsp;Our most advanced product candidate, Iomab-B, is
comprised of an anti-CD45 monoclonal antibody labeled with iodine-131 (I-131). We are currently conducting a pivotal Phase 3 trial
of Iomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or
refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow transplant is a potentially curative treatment option for
patients with AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as certain blood disorders.
Upon successful completion of our Phase 3 clinical trial for Iomab-B we intend to submit for marketing approval in the U.S. and
European Union. Our most advanced alpha-particle based therapy, Actimab-A, is an anti-CD33 monoclonal antibody conjugated with
the alpha-particle actinium-225 (Ac-225).&nbsp; Actimab-A is currently in a Phase 2 clinical trial for patients over the age of
60 who are newly diagnosed with AML and ineligible for standard induction chemotherapy. Actimab-M, our third product candidate,
is the same anti-CD33 monoclonal antibody conjugated to Ac-225 but a different dose and dosing regimen.&nbsp; Actimab-M, is being
studied in a Phase 1 trial for patients with refractory multiple myeloma. We expect our alpha-particle technology platform will
generate additional drug candidates that we will progress in clinical trials ourselves and or out-license. We intend to develop
a number of products for numerous types of cancer and derive revenue from partnering relationships worldwide and/or direct sales
of our products primarily in the United States.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2015, we announced that the
U.S. Food and Drug Administration, or FDA, cleared our IND filing for Iomab-B. In June 2016, we announced the pivotal Phase 3 clinical
trial for Iomab-B was initiated, and assuming that the trial meets its end points, it will form the basis for a Biologics Licensing
Application (BLA). We established an agreement with the FDA that the path to a BLA submission would include a single, pivotal Phase
3 clinical study if it is successful. The population in this two arm, randomized, controlled, multicenter trial will be patients
with relapsed or refractory AML over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary
endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least six months
and the secondary endpoint will be overall survival at one year. We believe there are currently no effective treatments approved
by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physicians-sponsored
clinical trials examining its potential as a myeloconditioning regimen prior to BMT in various blood cancers, including the Phase
1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential
of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do
not have any viable treatment options currently; enabling a shorter and safer preparatory interval for BMT; reducing post-transplant
complications; and showing a clear survival benefit including curative potential.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">In September 2016, we initiated a Phase
2 clinical trial for Actimab-A. This Phase 2 clinical trial is a multicenter, open-label study that will enroll 53 patients. Patients
will receive 2.0 &micro;Ci/kg/fractionated dose of Actimab-A via two injections given at day 1 and day 7. The Phase 2 trial is
designed to evaluate complete response rates at up to day 42 after Actimab-A administration, including complete remission (CR),
complete remission with incomplete platelet recovery (CRp) or complete remission with incomplete blood count recovery (CRi) A
formal interim analysis is scheduled for 31 patients, which is expected by the end of 2017. The Phase 2 clinical trial includes
peripheral blast burden as an inclusion criteria and in patients with high peripheral blast (PB) burden, the use of Hydroxyurea
will be mandated with the goal of bringing peripheral blasts below 200/&micro;L, which we identified from two previously complete
Phase 1 clinical trials totaling 38 patients. In addition, the use of granulocyte colony-stimulating factors (GCSF) will be mandated.
Low dose cytarabine has been eliminated from the protocol and the Phase 2 clinical trial will evaluate Actimab-A as a monotherapy.
The secondary endpoint of the Phase 2 clinical trial will be overall survival.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">In February 2017, we initiated a Phase 1
investigator initiated clinical trial to study Actimab-M in multiple myeloma. Multiple myeloma is a cancer of plasma cells
that is currently incurable. The Phase 1 trial will enroll up to 12 patients with relapsed or refractory multiple myeloma who have
positive CD33 expression. This Phase 1 study is designed as a dose escalation study intended to assess safety, establish maximum
tolerable dose (MTD) and assess efficacy. Patients will be administered Actimab-M on day 1 at an initial dose of 0.5 &micro;Ci/kg
and then assessed at day 42 for safety and efficacy. The dose can be increased to 1.0 &micro;Ci/kg or reduced to 0.25 &micro;Ci/kg
based on safety assessment that will evaluate dose limiting toxicities (DLTs). Patients may receive up to 8 cycles of therapy but
in no event will cumulative administration exceed 4.0 &micro;Ci/kg of Actimab-M.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>Business Strategy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.25pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">We intend to develop our most advanced clinical stage candidate, Iomab-B, through approval and
if these efforts are successful, we may elect to commercialize Iomab-B on our own or with a partner in the United States
and/or outside of the United States to out-license the rights to develop and commercialize the product to a strategic partner.
We intend to develop Actimab-A and Actimab-M through Phase 2 proof of concept human clinical trial (a trial designed to provide
data on the drug&rsquo;s efficacy) and we will most likely seek to enter into strategic partnerships whereby the strategic partner(s)
co-fund(s) further human clinical trials of the drug that are needed to obtain regulatory approvals for commercial sale within
and outside of the United States. In parallel, we intend to identify and begin initial human trials with additional actinium-225
based product candidates in other cancer indications. We intend to retain marketing rights for our products in the United States
whenever possible and out-license marketing rights to our partners for the rest of the world. We may also seek to in-license other
applicable opportunities should such technology become available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Market Opportunity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.25pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">We compete in the marketplace for
cancer treatments estimated to reach over $83 billion in 2016 sales, according to &ldquo;The Global Use of Medicines: Outlook
Through 2016 Report by the IMS Institute for Healthcare Informatics, July 2012.&rdquo; While surgery, radiation and
chemotherapy remain staple treatments for cancer, their use is limited by the fact that they often cause substantial damage
to normal cells. On the other hand, targeted monoclonal antibody therapies exert most or all of their effect directly on
cancer cells, but often lack sufficient killing power to eradicate all cancer cells with just the antibody. A new approach
for treating cancer is to combine the precision of antibody-based targeting agents with the killing power of radiation or
chemotherapy by attaching powerful killing agents to precise molecular carriers called monoclonal antibodies (mAb). We use
mAbs labeled with radioisotopes to deliver potent doses of radiation directly to cancer cells while sparing healthy tissues.
The radioisotopes we use are the alpha emitter Ac-225 and the beta emitter I-131. I-131 is among the best known and well
characterized radioisotopes. It is used very successfully in treatment of papillary and follicular thyroid cancer as well as
other thyroid conditions. It is also attached to a monoclonal antibody in treatment of Non-Hodgkin&rsquo;s Lymphoma
(&ldquo;NHL&rdquo;) and is also used experimentally with different carriers in other cancers. Ac-225 has many unique
properties and we believe we are a leader in developing this alpha emitter for clinical applications using our proprietary
alpha particle technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our most advanced products are
Iomab-B, I-131 labeled anti-CD45 mAb for myeloablation of relapsed or refractory AML patients pripr to a BMT and Actimab-A,
Ac-225 conjugated to an anti-CD33 mAb for treatment of newly diagnosed AML, in patients ineligible for currently approved
therapies. We recently began clinical development of Actimab-M, Ac-225 conjugated to an anti-CD33 mAb for the treatment of
patients with refractory multiple myeloma. Iomab-B offers a potentially curative treatment for these patients, most of whom
do not survive beyond one year after being diagnosed with this condition. Iomab-B has also demonstrated efficacy in BMT
preparation for other blood cancer indications, including myelodysplastic syndrome (&ldquo;MDS&rdquo;), acute lymphoblastic
leukemia (&ldquo;ALL&rdquo;), Hodgkin&rsquo;s Lymphoma, multiple myeloma and NHL. These are all follow-on indications for
which Iomab-B can be developed and it is our intention to explore these opportunities at a future date. We believe the
aggregate worldwide market potential for the treatment of AML, MDS, ALL, Hodgkin&rsquo;s Lymphoma, multiple myeloma and NHL
is approximately $4.1 billion.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2015, we announced that the
FDA cleared our IND filing for Iomab-B, and that we proceeded with a pivotal, Phase 3 clinical trial. We anticipate the Phase 3,
controlled, randomized, pivotal trial will complete enrollment of patients by 2018 and assuming that the trial meets its endpoints,
it will form the basis for a BLA. We, in our recently approved IND filing, established an agreement with the FDA that the path
to a BLA submission would include a single, pivotal Phase 3 clinical study if it is successful. The population in this two arm,
randomized, controlled, multicenter trial will be refractory and relapsed AML patients over the age of 55. The trial size was set
at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined
as a complete remission lasting at least six months and the secondary endpoint will be overall survival at one year. There are
currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care.
Iomab-B has completed several physicians sponsored clinical trials examining its potential as a conditioning regimen prior to BMT
in various blood cancers, including the Phase 1/2 clinical trial in relapsed and/or refractory AML patients. The results of these
clinical trials in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow
transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter
and safer preparatory interval for BMT; reducing post-transplant complications; and showing a clear survival benefit including
curative potential.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Other potential product opportunities in
which significant preclinical work is being undertaken include metastatic colorectal cancer, metastatic prostate cancer and antiangiogenesis
which reduces the blood supply to solid tumors. We believe the worldwide market potential for the treatment of metastatic colorectal
cancer is approximately $4.8 billion, and we believe the worldwide market potential for the treatment of metastatic prostate cancer
is approximately $6.0 billion. We also believe the worldwide market potential for the treatment of Glioblastoma Multiforme, a potential
indication based on an antiangiogenesis approach, is approximately $1.1 billion. We estimate the market potential for these indications
based on company research, published rates of disease incidence and company calculations based on costs of currently used therapies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that our biggest market opportunity
lies in the applicability of our alpha particle technology platform to a wide variety of cancer indications. A broad range of solid
and blood borne cancers can be potentially targeted by mAbs to enable treatment with the alpha-particle technology. We believe
that our alpha-particle technology could potentially be applied to mAbs that are already approved by the FDA to create more efficacious
and/or safer drugs (&ldquo;biobetters&rdquo;).</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">In March 2016, the FDA granted orphan drug designation for Iomab-B and in October 2016 the European
Medicines Agency (EMA) granted orphan designation in the European Union (EU) for Iomab-B. In November 2014, the FDA granted
orphan-drug designation for Actimab-A and in May 2017 the EMA granted orphan designation in the EU for Actimab-A. The FDA, through
its Office of Orphan Products Development, grants orphan status to drugs and biologic products that are intended for the safe and
effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the United
States. Orphan drug designation provides a drug developer with certain benefits and incentives, including a period of marketing
exclusivity if regulatory approval is ultimately received for the designated indication; potential tax credits on United States
clinical trials; eligibility for orphan drug grants; and waiver of certain administrative fees. The EMA, through its Committee
for Orphan Medicinal Products (COMP), examines applications for orphan designation. To qualify for orphan designation, the prevalence
of the condition must be less than 5 in 10,000, it must be life-threatening or chronically debilitating and there must be no satisfactory
method of treating the condition. Sponsors who obtain orphan designation receive numerous incentives including protocol assistance,
a reduction or waving of fees and 10 years of market exclusivity should the therapy be approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Clinical Trials</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Iomab-B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Iomab-B is our lead product candidate currently
in a pivotal Phase 3 multicenter clinical trial. It consists of the anti-CD45 monoclonal antibody BC8 and beta emitting radioisotope
iodine 131 (I-131). The indication for that trial is bone marrow conditioning for BMT in patients with relapsed and refractory
AML over the age of 55.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Previous Iomab-B clinical trials leading to the Phase 3 trial included:</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indications</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key Findings</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AML, MDS, ALL (adult)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;7/34 patients with median disease free state (DFS) of 17 years.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;18/34 patients in remission at day 80</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AML &gt;1st remission (adult)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;15/23 in remission at day 28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AML 1st remission (age 16-50)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;23/43 DFS from 5-16 years</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;30/43 in remission at day 28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;33/43 in remission at day 80</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High-risk MDS, advanced AML</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68 in dose escalation study</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;CR (complete remission) in all patients</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(age 50+)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31 treated at MTD</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;1 yr survival ~40% for all patients</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;1 yr survival ~45% for pts treated at MTD maximum tolerated dose)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High-risk MDS, AML</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(age 18&ndash;50)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14 in dose escalation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All patients achieved full donor chimerism by day 28 post-transplant</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High-risk MDS, AML</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;haploidentical donors (adult)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8 in dose escalation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;6/8 treated patients achieved CR by day 28</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;8/8 patients 100% donor chimerism by day 28</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Ongoing Iomab-B clinical trials include:</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indications</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relapsed and refractory Hodgkin Lymphoma and NHL (adult)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced AML, ALL and MDS (adult)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AML 1st remission (age 16-50)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High-risk MDS, advanced AML (age 16-50)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">There are additional ongoing clinical trials
with BC8 antibody labeled with yttrium 90 (Y-90).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Phase 3 Iomab-B clinical trial:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">We obtained FDA&rsquo;s comment and guidance on the Iomab-B Phase 3 clinical trial design, and
the FDA identified the following design features as generally acceptable, dependent on the results of the trial:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Single pivotal study, pending trial results;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient population: refractory AML patients age of 55 and older, where refractory is defined as either primary failure to achieve a complete remission after 2 cycles of induction therapy; relapsed after 6 months in complete remission; second or higher relapse; or relapsed disease not responding to intensive salvage therapy;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trial arms: study arm and control arm with physician&rsquo;s choice of conventional care with curative intent; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trial size: 150 patients total (75 patients per arm).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Actimab-A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68.8pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Actimab-A is currently in the Phase 2 portion
of a multicenter Phase 1/2 clinical trial in AML. It consists of the anti-CD33 monoclonal antibody Lintuzumab and alpha emitting
radioisotope actinium 225 (Ac-225). The indication in the ongoing trial is patients newly diagnosed with AML over the age of 60
that are ineligible for standard induction chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68.8pt; text-align: justify; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Previous clinical trials leading to this
trial included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 88.8pt; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1 clinical trial with Bismab-A, the first generation product consisting of the same anti-CD33 monoclonal antibody Lintuzumab and Bi-213 alpha emitter, a daughter of Ac-225;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1/2 clinical trial with Bismab-A, the first generation product consisting of the same monoclonal antibody Lintuzumab and Bi-213 alpha emitter, a daughter of Ac-225; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose escalating pilot Phase 1 clinical trial with Actimab-A, the current product consisting of the Lintuzumab monoclonal antibody and Ac-225 alpha emitter.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 88.8pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Completed Actimab-A related clinical trials
outcomes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 88.8pt; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Phase 2 arm of the Bismab-A drug study has shown signs of the drug&rsquo;s efficacy and safety, including reduction in peripheral blast counts and complete responses in some patients. Bi-213 is a daughter, i.e., product of the degradation of Ac-225, with cancer cell killing properties similar to Ac-225 but is less potent. The Phase 1 Actimab-A trial at MSKCC with a single-dose administration of Actimab-A showed elimination of leukemia cells from blood in 67% of all evaluable patients who received a full dose and in 83% of those treated at dose levels above 0.5 microcuries per kilogram (&micro;Ci/kg), and eradication of leukemia cells in both blood and bone marrow in 20% of all evaluable patients and 25% of those treated at dose levels above 0.5 &micro;Ci/kg. Maximum tolerated single dose in this trial was established at 3 &micro;Ci/kg.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">High potency means that a relatively low
amount of drug is needed to produce a given effect. In preclinical and Phase 1 clinical studies, Actimab-A (<SUP>225</SUP>Ac-lintuzumab)
has demonstrated at least 500-1000 times higher potency than the first-generation predecessor (<SUP>213</SUP>Bi-lintuzumab) upon
which it is based. This difference is due to intrinsic physicochemical properties of Actimab-A that were first established <I>in
vitro</I>, in which Actimab-A killed multiple cell lines at doses at least 1000 times lower (based on LD50 values) than Bismab-A
analogs. Key factors in Actimab-A&rsquo;s higher potency are the yield of 4 alpha-emitting isotopes per <SUP>225</SUP>Ac (compared
to 1 alpha decay for bismuth 213) and much longer half-life (10 day for <SUP>225</SUP>Ac vs 46 minutes for <SUP>213</SUP>Bi).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68.8pt; text-indent: 19.95pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">In preclinical animal models, doses in the
nanocurie range prolonged survival. In humans, Actimab-A was previously studied in a Phase I monotherapy trial of relapsed or refractory
AML patients at MSKCC. Dose levels in that study re-confirmed the substantially higher potency of Actimab-A, as compared to equivalent
dosing of the first-generation Bismab-A (<SUP>213</SUP>Bi-lintuzumab) construct, which had nevertheless established safety and
efficacy in a Phase 1/2 trial in high-risk AML with cytoreduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Sources: Jurcic JG. Targeted Alpha-Particle
Immunotherapy with Bismuth-213 and Actinium-225 for Acute Myeloid Leukemia. J. Postgrad Med Edu Res 2013, 47(1):14-17; ; JG Jurcic
et al, Phase 1 Trial of the Targeted Alpha- Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab in Acute Myeloid Leukemia (AML)
J Clin Oncol 29:2011 (suppl, abstr 6516); McDevitt MR et al, &ldquo;Tumor Therapy with Targeted Atomic Nanogenerators&rdquo; Science
2001, 294:1537&mdash;1540; Rosenblat TL et al, &ldquo;Sequential cytarabine and alpha-particle immunotherapy with bismuth- 213-lintuzumab
(HuM195) for acute myeloid leukemia&rdquo; Clin Cancer Res. 2010, 16(21):5303-5311; Jurcic JG et al. &ldquo;Phase I Trial of the
Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab in Acute Myeloid Leukemia (AML)&rdquo; Blood (ASH Meeting
Abstracts) 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ongoing Actimab-A trial:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68.8pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">We have completed the Phase 1 portion of
our first company sponsored Phase 1/2 multi-center trial with fractionated (two) doses of Actimab-A, for the treatment of patients
newly diagnosed with AML over the age of 60. Actimab-A consists of an anti-CD33 monoclonal antibody (HuM195, also known as Lintuzumab)
and the actinium 225 radioactive isotope attached to it. Results from the Phase 1 portion of the trial showed that 28% (5 of 18)
of patients had objective responses (2CR, 1CRp and 2 CRi (complete remission with incomplete blood count recovery)) with median
response duration of 9.1 months. Mean bone marrow blast reduction amongst evaluable patients (14 of 18) was 67% with 57% of patients
having bone marrow blast reduction of 50% or greater and 79% (11 of 14) of patients having bone marrow blast reductions after Cycle
1 of therapy. Maximum tolerated dose (MTD) was not reached in this trial. We have elected to progress to the Phase 2 portion of
the trial at 2.0 &mu;Ci/kg/fraction, the highest dose level from the Phase 1 portion of the clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">The Phase 2 portion of the trial will enroll
53 patients and will study Actimab-A as a monotherapy. We received agreement from the FDA for multiple revisions to the protocol
for the Phase 2 portion of the clinical trial that include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Removing the use of low dose cytarabine from the Phase 2 protocol;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stipulating Peripheral blast burden as an inclusion criteria with blasts of 200/ML being the threshold;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mandating the use of hydroxyurea in patients with peripheral blast count above 200/ML to lower their peripheral blasts below 200ML/ prior to Actimab-A administration; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mandating the use of granulocyte colony-stimulating factor (GCSF) support.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Bismab-A trials and the Phase 1 Actimab-A
trial were focused on relapsed, refractory and other difficult to treat acute myeloid leukemia patients. The current Actimab-A
multicenter Phase 1/2 trial is focused on patients newly diagnosed AML who have historically had better outcomes.&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Intellectual Property</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have developed or in-licensed numerous patents and patent applications and possess substantial know-how
and trade secrets relating to the development and manufacturing of our products. As of October 12, 2017, our patent portfolio includes:
68 issued and pending patent applications, of which 10 are issued in the United States, 15 are pending in the United States, and
53 are issued internationally and pending internationally. Additionally, several non-provisional patent applications are expected
to be filed in 2018 based on provisional patent applications filed in 2017. This is part of an ongoing strategy to continue to
strengthen our intellectual property position. About one quarter of our patents are in-licensed from third parties and the remainder
are Actinium-owned. These patents cover key areas of our business, including use of the actinium-225 and other alpha emitting isotopes
attached to cancer specific carriers like monoclonal antibodies, methods for manufacturing key components of our product candidates
including actinium-225, the alpha emitting radioisotope and carrier antibodies, and methods for manufacturing finished product
candidates for use in cancer treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have licensed the rights to two issued patents in the area of drug preparation for methods of making
humanized antibodies for our product Actimab-A that will expire in 2018 and 2019, respectively. We own three issued patents and
one pending patent in the United States and thirty-two patents outside of the United States related to the manufacturing of actinium
in a cyclotron that will expire in 2027. We own or have licensed the rights to four issued patents and 1 pending patent in the
United States and twenty-one patents outside of the United States related to the generation of radioimmunoconjugates that will
expire in 2021, 2030 and 2032, respectively. We own or have licensed the rights to use one issued patent, one pending patent and
two provisional patents for methods of treatment with our product Actimab-A that will expire in 2019. For Iomab-B we own
one pending patent for anti-CD45 immunoglobulin composition and one pending patent the administration of a conjugated antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">A patent whose claims address methods of treating hematopoietic malignancies with Iomab-B is pending;
still, we have developed a proprietary strategy based on trade secret protection and the potential for orphan drug and data exclusivities.
The BC8 antibody, cell line and related know-how has been exclusively licensed by us from the Fred Hutchinson Cancer Research Center
(FHCRC) in exchange for milestone payments, royalties and research support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Patents related to the antibody component of Actimab-A have been exclusively licensed by us from AbbVie
Biotherapeutics Corp. for use with alpha-emitting radioisotopes in exchange for future development and commercialization milestones,
a royalty on net sales for a period of 12.5 years from first commercial sale, a negotiation right to be our clinical and/or commercial
antibody supplier, a negotiation right to co-promote Actimab-A in the United States on terms to be negotiated, and the grant-back
of intellectual property (IP) rights covering improvements to the antibody for use other than with an alpha-emitting isotope. Patents
covering actinium-225 conjugated to antibodies have been exclusively licensed by us from MSKCC in exchange for license fees, research
support payments, development milestone payments, 2% royalties on net sales for the term of the licensed patents or, if later,
10 years from first commercial sale, and 15% of any sublicense income we may receive. We source actinium-225 under an agreement
with the Oak Ridge National Laboratory (ORNL) that expires at the end of 2017. We believe, but cannot guarantee, that we will be
able to renew this contract for additional annual periods.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate and Other Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">We were organized in the State of Nevada
on October 6, 1997 and reorganized in the State of Delaware on March 20, 2013. Our principal executive offices are located at 275
Madison, 7<SUP>th</SUP> Floor, New York, New York 10016. Our telephone number is (646) 677-3875. Our website address is www.actiniumpharma.com.
Information accessed through our website is not incorporated into this prospectus and is not a part of this prospectus.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>THE OFFERING</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock offered by us pursuant to this prospectus</FONT></TD>
    <TD STYLE="width: 6%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 47%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of our common stock having an aggregate offering price of up to $75,000,000.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manner of offering</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;At the market offering&rdquo; that may be made from time to time on a U.S national securities exchange or other market for our common stock in the U.S. through our agent, FBR. See the section entitled &ldquo;Plan of Distribution&rdquo; below.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">We currently intend to use the net proceeds from the
        sale of securities offered by this prospectus for general corporate purposes, including the advancement of
        our drug candidates in clinical trials, such as Iomab-B and Actimab-A, preclinical trials, and to meet working capital
        needs.</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">See the section entitled &ldquo;Use of Proceeds&rdquo;
        below.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;S-9 and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors you should carefully consider before deciding to invest in shares of our common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American symbol </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATNM.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An investment in our common stock
involves a high degree of risk. Before deciding whether to invest in our common stock, you should carefully consider the risks
and uncertainties described below, together with the information under the heading &ldquo;Risk Factors&rdquo; in our most recent
Annual Report on Form 10-K for the fiscal year ended December 31, 2016, all of which are incorporated herein by reference, as updated
or superseded by the risks and uncertainties described under similar headings in the other documents that are filed after the date
hereof and incorporated by reference into this prospectus, together with all of the other information contained or incorporated
by reference in this prospectus. The risks and uncertainties we have described are not the only ones we face. Additional risks
and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. Past financial
performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results
or trends in future periods. If any of these risks actually occurs, our business, business prospects, financial condition or results
of operations could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss
of all or part of your investment. Please also read carefully the section below entitled &ldquo;Special Note Regarding Forward-Looking
Statements.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Risks Relating to this Offering</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Our management team may invest
or spend the proceeds of this offering in ways with which you may not agree or in ways which may not yield a significant return.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management will have broad discretion
over the use of proceeds from this offering. We intend to use the net proceeds of this offering for the advancement of our drug
candidates in clinical trials, such as Iomab-B and Actimab-A, preclinical trials and for general corporate purposes.
However, our management will have broad discretion in the application of the net proceeds from this offering and could spend the
proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by management
to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause
the price of our common stock to decline and delay the development of our product candidates.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Purchasers in this offering
will likely experience immediate and substantial dilution in the book value of their investment.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because the price per share at which shares of our common stock are sold in this offering may be substantially
higher than the book value per share of our common stock, you may suffer immediate and substantial dilution in the net tangible
book value of the common stock you purchase in this offering. The shares sold in this offering, if any, will be sold from time
to time at various prices. After giving effect to the sale of our common stock in the maximum aggregate offering amount of $75,000,000
at an assumed offering price of $1.40 per share, the last reported sale price of our common stock on the NYSE American on February
27, 2017, and after deducting estimated offering commissions payable by us, our net tangible book value as of December 31, 2016
would have been $90.8 million, or $0.87 per share of common stock. This represents an immediate increase in the net tangible book
value of $0.51 per share to our existing stockholders and an immediate and substantial dilution in net tangible book value of $0.57
per share to new investors who purchase our common stock in the offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Sales of a substantial number
of shares of our common stock, or the perception that such sales may occur, may adversely impact the price of our common stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Almost all of our 79,380,158 outstanding shares of common stock as of October 11, 2017, as well as a substantial
number of shares of our common stock underlying outstanding options and warrants, are available for sale in the public market,
either pursuant to Rule 144 under the Securities Act of 1933, as amended, or an effective registration statement. Pursuant to this
shelf registration statement on Form S-3, we may sell up to $200,000,000 of our equity securities over the next several years.
Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely impact
the price of our common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Organization and Our Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Our corporate charter and bylaws
and Delaware law contain anti-takeover provisions that could delay or discourage takeover attempts that stockholders may consider
favorable.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors is authorized
to issue shares of preferred stock in one or more series and to fix the voting powers, preferences and other rights and limitations
of the preferred stock. Accordingly, we may issue shares of preferred stock with a preference over our common stock with respect
to dividends or distributions on liquidation or dissolution, or that may otherwise adversely affect the voting or other rights
of the holders of common stock. Issuances of preferred stock, depending upon the rights, preferences and designations of the preferred
stock, may have the effect of delaying, deterring or preventing a change of control, even if that change of control might benefit
our stockholders.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we are subject to Section
203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation from engaging in a &ldquo;business
combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years after the date of the transaction in
which the person became an interested stockholder, unless (i) prior to the date of the transaction, the board of directors of the
corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested
stockholder; (ii) the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time
the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who
are directors and also officers and (b) shares owned by employee stock plans in which employee participants do not have the right
to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or (iii) on
or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or
special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
stock which is not owned by the interested stockholder.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus and the information
incorporated by reference in this prospectus contain &ldquo;forward-looking statements,&rdquo; which include information relating
to future events, future financial performance, strategies, expectations, competitive environment and regulation. Words such as
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions, as well as statements in future tense, identify forward-looking
statements. Forward-looking statements should not be read as a guarantee of future performance or results and will probably not
be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information
we have when those statements are made or our management&rsquo;s good faith belief as of that time with respect to future events,
and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed
in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited
to:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to complete clinical trials as anticipated and obtain and maintain regulatory approvals for our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to adequately protect our intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes over ownership of intellectual property;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our dependence on an
    outside single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to
    increase production as necessary;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our products are an attractive alternative to other procedures and products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entry of new competitors and products and potential technological obsolescence of our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of a key
    supplier;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse economic conditions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse federal, state and local government regulation, in the United States;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">price increases for supplies and components;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to carry out research, development and commercialization plans; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss or retirement of key executives and research scientists.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should review carefully the section
entitled &ldquo;Risk Factors&rdquo; beginning on page&nbsp;S-9 of this prospectus for a discussion of these and other risks that
relate to our business and investing in our common stock. The forward-looking statements contained or incorporated by reference
in this prospectus are expressly qualified in their entirety by this cautionary statement. We do not undertake any obligation to
publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is
made or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The amount of proceeds from this
offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can
be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with FBR as a source of financing.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Unless otherwise indicated in the prospectus supplement, we currently intend to use the net proceeds from
the sale of securities offered by this prospectus for general corporate purposes, including, the advancement of our drug candidates
in clinical trials, such as Iomab-B, Actimab-A and Actimab-M, research and development of our alpha particle technology
platform, preclinical trials, and to meet working capital needs.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Investors are cautioned, however,
that expenditures may vary substantially from these uses. Investors will be relying on the judgment of our management, who will
have broad discretion regarding the application of the proceeds of this offering. The amounts and timing of our actual expenditures
will depend upon numerous factors, including the amount of cash generated by our operations, the amount of competition and other
operational factors. We may find it necessary or advisable to use portions of the proceeds from this offering for other purposes.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, we evaluate these
and other factors and we anticipate continuing to make such evaluations to determine if the existing allocation of resources, including
the proceeds of this offering, is being optimized. Circumstances that may give rise to a change in the use of proceeds include:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a change in development plan or strategy;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the addition of new products or applications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">technical delays;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays or difficulties with our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative results from our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty obtaining U.S. Food and Drug Administration approval;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to achieve sales as anticipated; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of other sources of cash including cash flow from operations and new bank debt financing arrangements, if any.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pending other uses, we intend to
invest the proceeds to us in investment-grade, interest-bearing securities such as money market funds, certificates of deposit,
or direct or guaranteed obligations of the U.S. government, or hold as cash. We cannot predict whether the proceeds invested will
yield a favorable, or any, return.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following description of common
stock and preferred stock summarizes the material terms and provisions of the common stock and preferred stock that we may offer
under this prospectus, but is not complete. For the complete terms of our common stock and preferred stock, please refer to our
certificate of incorporation, as amended and our bylaws, as may be amended from time to time. While the terms we have summarized
below will apply generally to any future common stock or preferred stock that we may offer, we will describe the specific terms
of any series of preferred stock in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement,
the terms of any preferred stock we offer under that prospectus supplement may differ from the terms we describe below.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have authorized 250,000,000 shares
of capital stock, par value $0.001 per share, of which 200,000,000 are shares of common stock and 50,000,000 are shares of preferred
stock. On October 11, 2017, there were 79,380,158 shares of common stock issued and outstanding and no shares of preferred stock
issued and outstanding. The authorized and unissued shares of common stock and the
authorized and undesignated shares of preferred stock are available for issuance without further action by our stockholders, unless
such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. Unless approval
of our stockholders is so required, our board of directors does not intend to seek stockholder approval for the issuance and sale
of our common stock or preferred stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also have warrants that are outstanding,
which are described below.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The holders of our common stock are
entitled to one vote per share. Our certificate of incorporation does not provide for cumulative voting. Our directors are divided
into three classes. At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire are
elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election. The holders
of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our board of directors out of
legally available funds; however, the current policy of our board of directors is to retain earnings, if any, for operations and
growth. Upon liquidation, dissolution or wind-up, the holders of our common stock are entitled to share ratably in all assets
that are legally available for distribution. The holders of our common stock have no preemptive, subscription, redemption or conversion
rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by,
the rights of the holders of any series of preferred stock, which may be designated solely by action of our board of directors
and issued in the future.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Our common stock is listed on the NYSE American
under the symbol &ldquo;ATNM.&rdquo;</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The board of directors is authorized,
subject to any limitations prescribed by law, without further vote or action by the stockholders, to issue from time to time shares
of preferred stock in one or more series. Each such series of preferred stock shall have such number of shares, designations,
preferences, voting powers, qualifications, and special or relative rights or privileges as shall be determined by the board of
directors, which may include, among others, dividend rights, voting rights, liquidation preferences, conversion rights and preemptive
rights. Issuance of preferred stock by our board of directors may result in such shares having dividend and/or liquidation preferences
senior to the rights of the holders of our common stock and could dilute the voting rights of the holders of our common stock.</P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to the issuance of shares of
each series of preferred stock, the board of directors is required by the Delaware General Corporation Law and our certificate
of incorporation to adopt resolutions and file a certificate of designation with the Secretary of State of the State of Delaware.
The certificate of designation fixes for each class or series the designations, powers, preferences, rights, qualifications, limitations
and restrictions, including, but not limited to, some or all of the following:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">the number of shares constituting that series and the distinctive designation of that series, which number may be increased or decreased (but not below the number of shares then outstanding) from time to time by action of the board of directors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">the dividend rate and the manner and frequency of payment of dividends on the shares of that series, whether dividends will be cumulative, and, if so, from which date;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">whether that series will have voting rights, in addition to any voting rights provided by law, and, if so, the terms of such voting rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">whether that series will have conversion privileges, and, if so, the terms and conditions of such conversion, including provision for adjustment of the conversion rate in such events as the board of directors may determine;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">whether or not the shares of that series will be redeemable, and, if so, the terms and conditions of such redemption;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">whether that series will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of such sinking fund;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">whether or not the shares of the series will have priority over or be on a parity with or be junior to the shares of any other series or class in any respect;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">the rights of the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation, and the relative rights or priority, if any, of payment of shares of that series; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">any other relative rights, preferences and limitations of that series.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Once designated by our board of directors,
each series of preferred stock may have specific financial and other terms that will be described in a prospectus supplement. The
description of the preferred stock that is set forth in any prospectus supplement is not complete without reference to the documents
that govern the preferred stock. These include our certificate of incorporation and any certificates of designation that our board
of directors may adopt.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All shares of preferred stock offered
hereby will, when issued, be fully paid and non-assessable, including shares of preferred stock issued upon the exercise of preferred
stock warrants or subscription rights, if any.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although our board of directors has
no intention at the present time of doing so, it could authorize the issuance of a series of preferred stock that could, depending
on the terms of such series, impede the completion of a merger, tender offer or other takeover attempt.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>Common Stock Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December 27, 2013 and January 10, 2014, we issued common stock warrants to certain investors in a private
placement of common stock and warrants (the &ldquo;Common Stock Warrants&rdquo;).&nbsp;&nbsp;The Common Stock Warrants have a five
year term from each closing that occurred on December 27, 2013 and January 10, 2014, and are exercisable for an aggregate of up
to 276,529 shares of our common stock at an initial per share exercise price of $9.00, subject to adjustments as set forth below.&nbsp;
As of October 11, 2017 we have 193,197 shares of Common Stock Warrants outstanding. We may also call this warrant for redemption
upon written notice to all warrant holders at any time the closing price of the common stock exceeds $15.00 (as may be adjusted
pursuant to warrant agreement) for 20 consecutive trading days, as reported by Bloomberg, provided at such time there is an effective
registration statement covering the resale of the shares underlying the warrants.&nbsp;&nbsp;In the 60 business days following
the date the redemption notice is deemed given in accordance with the agreement, investors may choose to exercise this warrant
or a portion of the warrant by paying the then applicable exercise price per share for every share exercised. Any shares not exercised
on the last day of the exercise period will be redeemed by us at $0.001 per share.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The exercise prices of the Common Stock Warrants are subject to adjustment upon certain events. If we
at any time while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding
Common Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights
under this warrant exist into a different number of securities of the same class, the exercise price for such securities shall
be proportionately decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>Series B Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Series B Warrants have a five year term from December 19, 2012 and are exercisable for an aggregate
of up to 1,559,505 shares of our common stock at an initial per share exercise price of $2.48, subject to adjustment as set forth
below.&nbsp;&nbsp;As of October 11, 2017, there were 1,317,195 warrants outstanding. These warrants have a cashless exercise provision.&nbsp;&nbsp;We
also have a right of first refusal on the holder&rsquo;s sale of the warrant shares.&nbsp;&nbsp;We may also call this warrant for
redemption upon written notice to all warrant holders at any time the closing price of the common stock exceeds $1.50 (as may be
adjusted pursuant to warrant agreement) for 20 consecutive trading days, as reported by Bloomberg, provided at such time there
is an effective registration statement covering the resale of the shares underlying the warrants.&nbsp;&nbsp;In the 60 business
days following the date the redemption notice is deemed given in accordance with the agreement, investors may choose to exercise
this warrant or a portion of the warrant by paying the then applicable exercise price per share for every share exercised.&nbsp;&nbsp;Any
shares not exercised on the last day of the exercise period will be redeemed by us at $0.001 per share.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The exercise price of the Series B Warrants is subject to adjustment upon certain events. If we at any
time while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common
Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this
warrant exist into a different number of securities of the same class, the exercise price for such securities shall be proportionately
decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, for so long as there are any warrants outstanding, if and whenever at any time and from time
to time after the warrant issue date, as applicable, we shall issue any shares of common stock for no consideration or a consideration
per share less than the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to
a proportional adjustment determined by multiplying such warrant exercise price by the following fraction:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">N(0) + N(1)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">N(0) + N(2)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 153pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Where:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 153pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">N(0) = the number of shares of common
stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of such additional shares of common stock
or common stock Equivalents;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 153pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">N(1) = the number of shares of common stock which the aggregate consideration, if any (including the aggregate
Net Consideration Per Share with respect to the issuance of common stock equivalents), received or receivable by us for the total
number of such additional shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price,
as applicable, in effect immediately prior to such issuance; and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">N(2) = the number of such additional
shares of common stock so issued or deemed to be issued.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 153pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 153pt"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 153pt"></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>Stock Offering Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Stock Offering Warrants have a term ending on January 31, 2019 and are exercisable for an aggregate
of up to 2,682,155 shares of our common stock at an initial per share exercise price of $0.78, subject to adjustment as set forth
below (anti-dilution).&nbsp;&nbsp;As of October 11, 2017, there were 1,239,997 warrants outstanding. These warrants have a cashless
exercise provision.&nbsp;&nbsp;We also have a right of first refusal on the holder&rsquo;s sale of the warrant shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These warrants have a cashless exercise provision.&nbsp;&nbsp;We also have a right of first refusal on
the holder&rsquo;s sale of the warrant shares.&nbsp;&nbsp;&nbsp;The exercise prices of the Stock Offering Warrants are subject
to adjustment upon certain events. If we at any time while the warrants remain outstanding and unexpired shall declare a dividend
or make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split, subdivide or combine the
securities as to which purchase rights under this warrant exist into a different number of securities of the same class, the exercise
price for such securities shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately
increased in the case of a combination.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>Consulting Firm Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Consulting Firm Warrants have a term ending on December 17, 2019 and are exercisable for an aggregate
of up to 3,755,560 shares of our common stock.&nbsp;&nbsp;As of October 11, 2017, there were 1,502,223 warrants outstanding. These
warrants may not be exercised by the Holder upon less than 90 days prior written notice of such exercise and provided further that
that the Holder may elect, in its sole discretion, to waive the Prior Notice Requirement, in whole or in part, upon 65 days prior
written notice of such waiver. These warrants have a cashless exercise provision and were issued at an initial
per share exercise price of $0.001, subject to adjustment as if we at any time while the warrants remain outstanding and unexpired
shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split,
subdivide or combine the securities as to which purchase rights under this warrant exist into a different number of securities
of the same class, the exercise price for such securities shall be proportionately decreased in the case of a dividend, split or
subdivision or proportionately increased in the case of a combination.&nbsp;&nbsp;The warrants are also subject to piggy-back registration
rights.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>2015 Offering Warrants</I>&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2015 Offering Warrants have a term ending February 11, 2019 and are exercisable for an aggregate of
up to 3,333,333 shares of our common stock at $6.50 per share. As of October 11, 2017, there were 3,333,333 warrants outstanding.
The exercise price and the number of warrant shares shall be adjusted from time to time if we at any time on or after the issuance
date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares
of common stock into a greater number of shares, the exercise price in effect immediately prior to such subdivision will be proportionately
reduced and the number of warrant shares will be proportionately increased.&nbsp;&nbsp;If we at any time on or after the issuance
date combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock
into a smaller number of shares, the exercise price in effect immediately prior to such combination will be proportionately increased
and the number of warrant shares will be proportionately decreased.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If at any time prior
to the expiration date we grant, issue or sell any Options, Convertible Securities or rights to purchase stock, warrants, securities
or other property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;Purchase Rights&rdquo;), then
the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which
the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of
this warrant (without regard to any limitations on the exercise of this warrant) immediately before the date on which a record
is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record
holders of shares of common stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however,
that to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the holder exceeding
the Maximum Percentage, then the holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent
shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Maximum Percentage (as defined in the warrant), at which time the Holder shall be granted such right to the same extent as
if there had been no such limitation).</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>Placement Agent Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We issued three types of warrants to the Placement Agent, Placement Agent Stock Offering Warrants, Placement
Agent Common Stock Warrants, and Placement Agent December 2013 Offering Warrants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>Placement Agent Stock Offering Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Placement Agent Stock Offering Warrants have a term ending on January 31, 2019 and are exercisable
for an aggregate of up to 1,251,022 shares of our common stock at an initial per share exercise price of $0.78, subject to adjustment
as set forth below (anti dilution).&nbsp;As of October 11, 2017, there were 355,293 warrants outstanding.&nbsp;These warrants have
a cashless exercise provision.&nbsp;The exercise prices of the warrants are subject to adjustment upon certain events. If we at
any time while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding
Common Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights
under this warrant exist into a different number of securities of the same class, the exercise price for such securities shall
be proportionately decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>Placement Agent Common Stock Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Placement Agent Common Stock Warrants have a five year term from January 28, 2013 and are exercisable
for an aggregate of up to 467,845 shares of our common stock at an initial per share exercise price of $2.48, subject to adjustment
as set forth below.&nbsp;&nbsp;As of October 11, 2017, there were 298,065 warrants outstanding. These warrants have a cashless
exercise provision.&nbsp;We may also call this warrant for redemption upon written notice to all warrant holders at any time the
closing price of the common stock exceeds $1.50 (as may be adjusted pursuant to warrant agreement) for 20 consecutive trading days,
as reported by Bloomberg, provided at such time there is an effective registration statement covering the resale of the shares
underlying the warrants.&nbsp;&nbsp;In the 60 business days following the date the redemption notice is deemed given in accordance
with the agreement, investors may choose to exercise this warrant or a portion of the warrant by paying the then applicable exercise
price per share for every share exercised.&nbsp;&nbsp;Any shares not exercised on the last day of the exercise period will be redeemed
by us at $0.001 per share.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The exercise prices of the warrants are subject to adjustment upon certain events. If we at any time while
the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable
in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this warrant exist
into a different number of securities of the same class, the exercise price for such securities shall be proportionately decreased
in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, for so long as there are any warrants outstanding, if and whenever at any time and from time
to time after the warrant issue date, as applicable, we shall issue any shares of common stock for no consideration or a consideration
per share less than the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to
a proportional adjustment determined by multiplying such warrant exercise price by the following fraction:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">N(0) + N(1)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">N(0) + N(2)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 153pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Where:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 153pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">N(0) = the number of shares of common
stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of such additional shares of common stock
or common stock Equivalents;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 153pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">N(1) = the number of shares of common stock which the aggregate consideration, if any (including the aggregate
Net Consideration Per Share with respect to the issuance of common stock equivalents), received or receivable by us for the total
number of such additional shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price,
as applicable, in effect immediately prior to such issuance; and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">N(2) = the number of such additional
shares of common stock so issued or deemed to be issued.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>Placement Agent December 2013 Offering Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Placement Agent December 2013 Offering Warrants have a five year term from January 10, 2014 and are
exercisable for an aggregate of up to 138,265 shares of our common stock at an initial per share exercise price of $9.00, subject
to adjustment as set forth below.&nbsp;As of October 11, 2017, there were 124,997 warrants outstanding.&nbsp;These warrants have
a cashless exercise provision. We may also call this warrant for redemption upon written notice to all warrant holders
at any time the closing price of the common stock exceeds $15.00 (as may be adjusted pursuant to warrant agreement) for 20 consecutive
trading days, as reported by Bloomberg, provided at such time there is an effective registration statement covering the resale
of the shares underlying the warrants.&nbsp;&nbsp;In the 60 business days following the date the redemption notice is deemed given
in accordance with the agreement, investors may choose to exercise this warrant or a portion of the warrant by paying the then
applicable exercise price per share for every share exercised.&nbsp;&nbsp;Any shares not exercised on the last day of the exercise
period will be redeemed by us at $0.001 per share.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The exercise prices of the warrants are subject to adjustment
upon certain events. If the Company at any time while the warrants remain outstanding and unexpired shall declare a dividend or
make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split, subdivide or combine the
securities as to which purchase rights under this warrant exist into a different number of securities of the same class, the exercise
price for such securities shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately
increased in the case of a combination.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>Consultant Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of October 11, 2017, we
had outstanding warrants exercisable for 507,833 shares of common stock issued to various consultants in consideration for
services. The exercise prices range from $0.98 to $11.66 per share. These warrants do not have a cashless exercise
provision.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>2017 Warrants</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July 2017 in connection with an offering, we issued warrants to purchase 18,275,000 shares of Common
Stock. The warrants are exercisable commencing on the issuance date at an exercise price equal to $1.05 per share of common stock,
subject to adjustments as provided under the terms of the warrants. The warrants are exercisable for five years from the date of
issuance. These warrants do have a cashless exercise provision.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_008"></A>DILUTION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you invest in our common stock,
your interest will be diluted to the extent of the difference between the price per share you pay in this offering and the net
tangible book value per share of our common stock immediately after this offering. Our net tangible book value of our common stock
as of December 31, 2016 was approximately $18.0 million, or approximately $0.32 per share of common stock based upon 55,801,742&nbsp;shares
outstanding at that time. &ldquo;Net tangible book value&rdquo; is total assets minus the sum of liabilities and intangible assets.
&ldquo;Net tangible book value per share&rdquo; is net tangible book value divided by the total number of shares outstanding.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After giving effect to the sale of our common stock at $0.001 par value in the aggregate amount of $75,000,000
at an assumed offering price of $1.40 per share, the last reported sale price of our common stock on the NYSE American on February
27, 2017, and after deducting estimated offering expenses payable by us, our net tangible book value as of December 31, 2016 would
have been $90.8 million, or $0.83 per share of common stock. This represents an immediate increase in net tangible book value of
$0.51 per share to our existing stockholders and an immediate dilution in net tangible book value of $0.57 per share to new investors
in this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table illustrates this
calculation on a per share basis as of December 31, 2016:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif">Assumed Public offering price per share of common stock</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.40</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Net tangible book value per share of common stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.32</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Increase in net tangible book value per share of common stock attributable to the offering</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.51</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Pro forma net tangible book value per share of common stock after giving effect to the offering</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Dilution in net tangible book value per share of common stock to new investors in the offering</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.57</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing table and calculations
are based on the number of shares of our common stock outstanding as of December 31, 2016.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A><B>DIVIDENDS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the past, we have not declared
or paid cash dividends on our common stock, and we do not intend to pay any cash dividends on our common stock. Rather, we intend
to retain future earnings, if any, to fund the operation and expansion of our business and for general corporate purposes.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into an At Market
Issuance Sales Agreement, or sales agreement, with FBR to issue and sell up to $75,000,000 worth of our common stock from time
to time under this prospectus. FBR will act as agent in the offering, subject to certain limitations, including the number of shares
registered under the registration statement to which the offering relates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The sales, if any, of shares made
under the sales agreement will be made by any method that is deemed an &ldquo;at the market offering&rdquo; as defined in Rule
415 promulgated under the Securities Act of 1933, as amended. We may instruct FBR not to sell common stock if the sales cannot
be effected at or above the price designated by us from time to time. We or FBR may suspend the offering of common stock upon notice
and subject to other conditions. As an agent, FBR will not engage in any transactions that stabilize the price of our common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each time we wish to issue and sell
common stock under the sales agreement, we will notify FBR of the number of shares to be issued, the dates on which such sales
are anticipated to be made, any minimum price below which sales may not be made and other sales parameters as we deem appropriate.
Once we have so instructed FBR, unless FBR declines to accept the terms of the notice, FBR has agreed to use its commercially reasonable
efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The
obligations of FBR under the sales agreement to sell our common stock are subject to a number of conditions that we must meet.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will pay FBR commissions for its
services in acting as agent in the sale of common stock. FBR will be entitled to a commission of 3% of the gross proceeds from
the sale of common stock offered hereby. In addition, we have agreed to reimburse certain expenses of FBR in an amount not to exceed
$25,000. FBR may also receive customary brokerage commissions from purchasers of the common stock in compliance with FINRA Rule
2121. FBR may effect sales to or through dealers, and such dealers may receive compensation in the form of discounts, concessions
or commissions from FBR and/or purchasers of shares of common stock for whom they may act as agents or to whom they may sell as
principal. We estimate that the total expenses for the offering, excluding compensation payable to FBR under the terms of the sales
agreement, will be approximately $0.1 million.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Settlement for sales of common stock
will occur on the third business day following the date on which any sales are made, or on some other date that is agreed upon
by us and FBR in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement
for funds to be received in an escrow, trust or similar arrangement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the sale of the
common stock on our behalf, FBR may, and will with respect to sales effected in an &ldquo;at the market offering&rdquo;, be deemed
to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act of 1933, as amended, and the compensation of FBR may
be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to FBR against
certain civil liabilities, including liabilities under the Securities Act of 1933, as amended. We have also agreed to reimburse
FBR for certain other specified expenses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The offering will terminate as permitted
under the sales agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FBR and its affiliates may in the
future provide various investment banking and other financial services for us and our affiliates, for which services they may in
the future receive customary fees. To the extent required by Regulation M, FBR will not engage in any market making activities
involving our common stock while the offering is ongoing under this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The validity of the securities offered
by this prospectus will be passed upon by The Matt Law Firm, PLLC, Utica, New York. Duane Morris LLP, Newark, New Jersey, is counsel
for FBR in connection with this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>EXPERTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The financial statements incorporated
in this prospectus by reference to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 have been so incorporated
in reliance on the report of GBH CPAs, PC an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are subject to the informational
requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith file annual, quarterly and current
reports, proxy statements and other information with the Securities and Exchange Commission. Such reports, proxy statements and
other information can be read and copied at the Securities and Exchange Commission&rsquo;s public reference facilities at 100 F
Street, N.E., Washington,&nbsp;D.C. 20549, at prescribed rates. Please call the Securities and Exchange Commission at 1-800-732-0330
for further information on the operation of the public reference facilities. In addition, the Securities and Exchange Commission
maintains a website that contains reports, proxy and information statements and other information regarding registrants that file
electronically with the Securities and Exchange Commission. The address of the Securities and Exchange Commission&rsquo;s website
is www.sec.gov.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We make available free of charge
on or through our website at www.actiniumpharmceuticals.com, our Annual Reports on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q,
Current Reports on Form&nbsp;8-K and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of
the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with
or otherwise furnish it to the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have filed with the Securities
and Exchange Commission a registration statement under the Securities Act of 1933, as amended, relating to the offering of these
securities. The registration statement, including the attached exhibits, contains additional relevant information about us and
the securities. This prospectus does not contain all of the information set forth in the registration statement. You can obtain
a copy of the registration statement, at prescribed rates, from the Securities and Exchange Commission at the address listed above,
or for free at www.sec.gov. The registration statement and the documents referred to below under &ldquo;Incorporation of Certain
Information By Reference&rdquo; are also available on our website, www.actiniumpharmaceuticals.com.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not incorporated by reference
into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_014"></A><B>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Securities and Exchange Commission
allows us to &ldquo;incorporate by reference&rdquo; the information we have filed with it, which means that we can disclose important
information to you by referring you to those documents. The information we incorporate by reference is an important part of this
prospectus, and later information that we file with the Securities and Exchange Commission will automatically update and supersede
this information. We incorporate by reference the documents listed below and any future documents (excluding information furnished
pursuant to Items 2.02 and 7.01 of Form 8-K) we file with the Securities and Exchange Commission pursuant to Sections l3(a), l3(c),
14 or l5(d) of the Securities Exchange Act of 1934, as amended, subsequent to the date of this prospectus and prior to the termination
of the offering:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2016, filed with the Securities and Exchange Commission on March 16, 2017;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Quarterly Report on Form 10-Q for the fiscal quarter ended March&nbsp;31, 2017, filed with the Securities and Exchange Commission on May 15, 2017;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2017, filed with the Securities and Exchange Commission on August 4, 2017;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our Current Report on Form 8-K, filed with the Securities and Exchange Commission on March 28, 2017;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 11, 2017;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 16, 2017;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our Current Report on Form 8-K/A, filed with the Securities and Exchange Commission on May 26, 2017;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 8, 2017;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>Our Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 9, 2017; &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 16, 2017;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 3, 2017;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>Our Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 28, 2017;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our common stock, which is contained in our Form 8-K/A, filed with the Securities and Exchange Commission on January 28, 2013.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All filings filed by us pursuant
to the Securities Exchange Act of 1934, as amended, after the date of the initial filing of this registration statement and prior
to the effectiveness of such registration statement (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K)
shall also be deemed to be incorporated by reference into the prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should rely only on the information
incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different information.
You should not assume that the information in this prospectus is accurate as of any date other than the date of this prospectus
or the date of the documents incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will provide without charge to
each person to whom a copy of this prospectus is delivered, upon written or oral request, a copy of any or all of the information
that has been incorporated by reference in this prospectus but not delivered with this prospectus (other than an exhibit to these
filings, unless we have specifically incorporated that exhibit by reference in this prospectus). Any such request should be addressed
to us at: 275 Madison Avenue, 7th Floor, New York, New York 10016, Attention: Steve O&rsquo;Loughlin, Principal Financial Officer,
or made by phone at (646) 677-3875. You may also access the documents incorporated by reference in this prospectus through our
website at <U>www.actiniumpharma.com</U>. Except for the specific incorporated documents listed above, no information available
on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which it forms
a part.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$75,000,000</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 103px; width: 428px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FBR</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is October
24, 2017</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !G :P# 2(  A$! Q$!_\0
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M6]W?6\JM<33#?&0#S&/KT)'X5ZC\'OC-H?QD\.B_TQ_L]]" +S3I3^]MV/\
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M6C:,QF0$=?E')^E9'C3XE:1XB_9O@TS2FFOKV&TL[:Z2*%]MLRL@.]B,#)7
M&>?I7TV% Z#%,6"-5VB-0N<[0HQGUHHYO3I\O-2;Y:GM%[W>VC]W7;R%B.':
MU;GY*Z7/15&7N7T5[27O:;ZIW/FWXD:U9M^R_H>FB4K?RP6D26S1LKLT90R
M C^'N>E;_C3Q+I=Q^S'!#'>QO+<:=!;11C.YY4,>] ,9R,'/TKW8J&Z@&DV+
M_='Y5,<V@E37LW[M1U/B[VT^'R1I+A^K)U7[9>_15'X7HE?WOB\WIZ?/P!?$
M&FS?LHS6J7D;7$>E_87BYW+.1Q'CUKM/V<[ZUN/A+HMM!,LD]JKQSQ_Q1N78
MX([<$'\:]+V+_='Y4JJ%Z #Z5SXC,(5J%2BH-<T^??RM;;S.S!Y-4PN+I8J5
M5/DI*E;EM>S3O?F=MMM1:***\0^H"BBB@ HHHH **** "BBB@ HHHH ****
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M,(3<:BV/T*\I13B=!??MA:O:YV7.B-_O6LG_ ,=KGK[]N37[7.U] ;ZVTO\
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MU\-VMK-;VTC""XN@5)^4K,\@'W I^ZHR=P_#9\$_%3Q')\4+OP/XKL+".^6
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M3=6OU/RE^+'[?WBV/XB:?)X':2VT32YU,DTL1V7J*<>6H(XC([]3VP.OZ)?
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M!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $(#=1GO2T44 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
